Until recently, genomics was a «read-only» science. But scientists led by Rory Johnson at the University of Bern and the Centre for Genomic Regulation in Barcelona, have now developed a tool for quick and easy deletion of DNA in living cells.
This software will boost efforts to understand the vast regions of non-coding DNA, or «Dark Matter», in our DNA and may lead to discovery of new disease-causing genes and potential new drugs.
Genomics is the field of research studying how our «genome», or entire DNA sequence, specifies a human being, and how errors in this sequence give rise to diseases. Genomics was recently a «read-only» endeavour: researchers used powerful technology to read genomes’ sequence and their regulatory layers. However until recently, there was no way to edit or delete DNA for either basic research objectives, or for potential therapeutic interventions.
Just a few years ago, this outlook changed dramatically with the discovery of a revolutionary technique for editing genomes: «CRISPR-Cas9». CRISPR-Cas9 is a molecular tool composed of two simple components: a molecular barcode, called «sgRNA», which is designed by the researcher to recognise one precise location in the genome; and a protein, Cas9, that binds to a structured loop in the sgRNA. By introducing these two units, researchers may perform a wide range of operations on specific pieces of genomic DNA, from introducing small mutations, to regulating gene activity, to tagging it with small sequences. Until recently most studies employing CRISPR-Cas9 were aimed at silencing protein-coding genes, the best-studied part of our genome.
However our genome consists of 99% of DNA that does not encode any protein. Often described as the «Dark Matter» of the genome, this «non-coding DNA» is recognised to be crucially important for understanding all aspects of human biology, including disease and evolution. Until recently, the experimental tools to study this have not been available.
Researchers studying non-coding DNA have been particularly excited about the discovery of CRISPR-Cas9 because it can be used as a powerful tool for studying non-coding DNA for the first time. Prof Rory Johnson, at the Centre for Genomic Regulation (CRG) in Barcelona, Spain and now at the National Center of Competence in Research (NCCR) RNA & Disease and Department of Clinical Research of the University of Bern, recently created a tool based on CRISPR-Cas9, called «DECKO», which can be used to delete any desired piece of non-coding DNA. The unique advantage of DECKO is that it uses two individual sgRNAs, acting like two molecular scissors that snip out a piece of DNA. Numerous researchers worldwide have adopted this approach, attracted by its simplicity and effectiveness.
While working on DECKO, Johnson and colleagues realised that no software was available for designing the pairs of sgRNAs that are required, meaning that designing deletion experiments was time-consuming. To overcome this, Johnson recruited Masters student Carlos Pulido to design a software pipeline called CRISPETa. They were assisted by a team of laboratory researchers including co-first authors of this paper Estel Aparicio and Carme Arnan, who carried out experiments to validate the software’s predictions.
CRISPETa is a powerful and flexible solution for designing CRISPR deletion experiments. The user tells CRISPETa what region they wish to delete, and the software returns a set of optimised pairs of sgRNAs that can directly be used by experimental researchers. One of the key features is that it can create designs at high scales, with future screening experiments in mind. Importantly, CRISPETa is designed for use by non-experts, and is available in a user friendly website, making CRISPR deletion available to the widest possible number of scientific and biomedical researchers.
In the CRISPETa study, the researchers also introduce a new version of DECKO, which is cheaper and faster than the previous one. The researchers showed that CRISPETa designs efficiently delete their desired targets in human cells. Most importantly, in those regions that give rise to RNA molecules, the researchers showed that the RNA molecules also carry the deletion.
CRISPETa will be useful for scientific researchers, from even the most modest experimental laboratory. These users may, for example, delete a suspected functional region of non-coding DNA, and test the outcome on cellular or molecular activity. This software will also be potentially valuable for groups aiming to utilise CRISPR deletion for therapeutic purposes, by for example, deleting a region of non-coding DNA that is suspected to cause a disease state. Therefore CRISPETa will be a valuable tool for the hundreds of research teams worldwide who are using CRISPR deletion.
«We hope that this new software tool will allow the greatest possible number of researchers to harness the power of CRISPR deletion in their research», says Carlos Pulido, the student who wrote the CRISPETa software.
«Ultimately, we expect that CRISPR deletion and other genome engineering tools to lead to a revolution in our ability to understand the genomic basis of disease, particularly in the 99% of DNA that does not encode proteins. Apart from being used as a basic research tool, CRISPR may even be used in the future as a powerful therapeutic to reverse disease-causing mutations», adds Rory Johnson.
Receive an email update when we add a new GENOMIC MEDICINE article.
The Latest on: Genomic medicine
via Google News
The Latest on: Genomic medicine
- Qatar Genome Programme, Genomics England ink pact on April 17, 2019 at 3:03 pm
The agreement lays the foundation for Qatar and the UK to develop a joint collaboration focusing on areas of research in genomics that can have a global impact. “This partnership aims to foster our ... […]
- Aevi Genomic Medicine (GNMX) Shares Gap Up to $0.23 on April 17, 2019 at 3:02 pm
Aevi Genomic Medicine Inc (NASDAQ:GNMX) shares gapped up prior to trading on Wednesday . The stock had previously closed at $0.25, but opened at $0.23. Aevi Genomic Medicine shares last traded at ... […]
- Genomic Medicine Market Share and Growth 2019| BioMed Central, Cleveland Clinic, MD Anderson Cancer Center, Manchester Centre for Genomic Medicine on April 17, 2019 at 2:22 pm
The report on the global Genomic Medicine market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, ... […]
- There's now a cure for the deadly genetic disorder known as 'bubble boy' disease on April 17, 2019 at 2:04 pm
A new experimental medicine is now being called a cure for the condition by researchers at St. Jude Children's Research Hospital. Ten babies born with the genetic disease, X-linked severe combined ... […]
- Four Companies Could Power The New Genomics ETF on April 17, 2019 at 11:10 am
genetic medicine/therapy, computational genomics, and biotechnology,” according to Global X. Companies are only eligible for inclusion if they generate at least 50% of their revenues from ... […]
- 4 Leading Companies In Genomics on April 17, 2019 at 11:05 am
Together, these trends in genomics should help accelerate the healthcare industry’s push towards personalized medicine and improve the health of millions suffering from genetic disorders worldwide. […]
- What's The Science Behind Genomics? on April 17, 2019 at 8:33 am
This blog post is the second in a two-part series exploring the disruptive impact of genomics on healthcare and medicine. To read the first part, which focuses on the catalysts supporting genomics ... […]
- Sutter Health, UPMC team up on precision medicine to improve multiple sclerosis treatments on April 16, 2019 at 11:48 am
RELATED: Geisinger Health plans to make DNA sequencing 'routine' part of care Scientists at the Sutter Health Center for Precision Medicine will input de-identified clinical-genomic data sets from ... […]
- RNA Therapeutics Startup Panorama Medicine Raises $3.7 Million to Accelerate Drug Discovery Using Genomics and Artificial Intelligence on April 16, 2019 at 5:36 am
PHILADELPHIA, April 16, 2019 /PRNewswire/ -- Panorama Medicine ("Panorama"), a genomics and computing powered drug discovery company focusing on RNA therapeutics, has raised a $3.7 million seed ... […]
via Bing News